Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Completed · Phase 2

Conditions studied: Adenocarcinoma of the Prostate, Prostate Cancer

In brief

The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: * stop or slow the growth of disease * gain information about prostate cancer * evaluate the effectiveness and side effects of the study drug

Key facts

Study ID

NCT00165399

Run by

Dana-Farber Cancer Institute

People needed

62

Starts

2004-03-01

Expected to finish

2005-12-31

Last updated by the study team

2018-06-25

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically documented adenocarcinoma of the prostate
• Previous treatment with either radical prostatectomy or radiation therapy
• Post prostatectomy: PSA rising on at least two successive occasions at least two weeks apart
• Post radiation therapy alone: PSA has to be rising as documented on two successive occasions at least two weeks apart and also have doubled from the nadir post treatment value
• ECOG performance status 0-1
• ANC > 1,500/mm3
• Platelet counts > 100,000/mm3
• SGOT and/or SGPT may be up to 2.5 x ULN

You may not qualify if…

• Documented local recurrence of prostate cancer or documented metastatic disease
• History of other malignancy within the last 5 years, other than curatively treated basal cell carcinoma of the skin
• Medical condition requiring the use of concommitant corticosteroids
• Active infection
• Significant cardiac disease, angina pectoris or myocardial infarction within six months
• Prior chemotherapy including estramustine, suramin
• Active thrombophlebitis or history of thromboembolic events in the six months preceding study treatment
• Clinically significant neuropathy
• Elevated bilirubin above ULN

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Lahey Clinic-Burlington — Burlington, Massachusetts, United States
• University of Massachusetts Memorial Medical Center-University Campus — Worcester, Massachusetts, United States
• Norris Cotton Cancer Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.